All Releases
 |
Athersys Reports First Quarter 2013 Results
May 14, 2013
|
26.1 KB |
|
| |
CLEVELAND, May 14, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended March 31, 2013. "Our focus remains on the advancement of our lead clinical programs, MultiStem for ulcerative colitis with our partner, Pfizer, and MultiStem for ischemic stroke, and on the development of new bus...
|
|
Athersys to Present at 12th Annual Needham Healthcare Conference
Apr 25, 2013
|
15.2 KB |
|
| |
CLEVELAND, April 25, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer, will present at the 12th Annual Needham Healthcare Conference to be held at The Westin New York Grand Central from April 30 - May 1, 2013 in New York City.
Details of Athersys' partic...
|
|
Athersys to Host First Quarter 2013 Financial Results Call
Apr 18, 2013
|
15.6 KB |
|
| |
CLEVELAND, April 18, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its first quarter 2013 financial results at approximately 4:00 PM (Eastern Time) on Tuesday, May 14, 2013, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen, Chairman and Chief Exec...
|
|
Athersys Announces Authorization of Stem Cell Clinical Trial for Stroke in the United Kingdom
Apr 17, 2013
|
17.7 KB |
|
| |
CLEVELAND, April 17, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Athersys' application to expand its ongoing Phase 2 study evaluating the administration of MultiStem® therapy to patients who have suffered an ischemic stroke. Enrollment at...
|
|
Athersys to Present at Regen Med Investor Day 2013 in New York
Apr 11, 2013
|
18.7 KB |
|
| |
CLEVELAND, April 11, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that Chairman and CEO, Gil Van Bokkelen, will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City.
Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Burri...
|
|
Publications Demonstrate Relevance of MultiStem(R) for Autoimmune Disease, Transplantation and Vascular Disease
Apr 10, 2013
|
20.3 KB |
|
| |
CLEVELAND, April 10, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the recent publication of articles in two peer-reviewed scientific journals, Journal of Immunology and Circulation, that describe the potential for multipotent adult progenitor cells (MAPC®s), or MultiStem® cells, to provide benefit in autoimmune di...
|
|
Athersys Reports Fourth Quarter and 2012 Annual Results
Mar 12, 2013
|
28.6 KB |
|
| |
CLEVELAND, March 12, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the fourth quarter and year ended December 31, 2012.
Fourth Quarter and 2012 Highlights:
Raised $21.2 million net proceeds in the fourth quarter, including the full exercise of underwriters' over-allotment optio...
|
|
Athersys to Host Fourth Quarter and Year-End 2012 Financial Results Call
Feb 25, 2013
|
15.8 KB |
|
| |
CLEVELAND, Feb. 25, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its fourth quarter and year-end 2012 financial results at approximately 4:00 PM (Eastern Time) on Tuesday, March 12, 2013, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen, Chairman...
|
|
Athersys Announces Adjournment of Special Meeting Date
Feb 21, 2013
|
18.2 KB |
|
| |
CLEVELAND, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has adjourned its special meeting of stockholders scheduled for 9:00 a.m. Eastern Time today, February 21, 2013, until 9:00 a.m. Eastern Time on Thursday, February 28, 2013, in order to ensure a quorum exists and to solicit additional proxies for a war...
|
|
Athersys to Present at New York Stem Cell Summit '13
Feb 13, 2013
|
14.8 KB |
|
| |
CLEVELAND, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 8th Annual New York Stem Cell Summit '13 Conference to be held Tuesday, February 19, 2013, in New York City.
As part of a panel entitled, "Disrupting the Pharma Model with Allogeneic Stem Cell Therapies," Athersys' participa...
|
|
Athersys to Present at BIO CEO & Investor Conference
Feb 11, 2013
|
15.2 KB |
|
| |
CLEVELAND, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer, will present at the 15th Annual BIO CEO & Investor Conference to be held Monday, February 11, 2013, through Tuesday, February 12, 2013, at The Waldorf Astoria New York in New York City.
...
|
|
Athersys Files Shelf Registration to Replace Expiring S-3 Registration Statement
Jan 11, 2013
|
16.3 KB |
|
| |
CLEVELAND, Jan. 11, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has filed a shelf registration statement with the Securities and Exchange Commission ("SEC"). The new shelf registration statement will replace a similar registration filed in 2010 that will expire later this month. Athersys currently does not have any...
|
|
Athersys to Present at Biotech Showcase(TM) 2013
Jan 7, 2013
|
16.9 KB |
|
| |
CLEVELAND, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that William (B.J.) Lehmann, President and Chief Operating Officer, will present at the Biotech ShowcaseTM 2013 Conference to be held January 7 through January 9, 2013 in San Francisco, California.
Details of Athersys' participation are as follows:
...
|
|
Athersys to Present at Piper Jaffray 24th Annual Healthcare Conference
Nov 19, 2012
|
15.2 KB |
|
| |
CLEVELAND, Nov. 19, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced that it will present at the Piper Jaffray 24th Annual Healthcare Conference, to be held Tuesday, November 27, 2012, through Wednesday, November 28, 2012, at The New York Palace in New York City.
William (B.J.) Lehmann, President and Chief Operating Off...
|
|
Athersys Named to Deloitte's 2012 Technology Fast 500(TM)
Nov 15, 2012
|
19.5 KB |
|
| |
CLEVELAND, Nov. 15, 2012 (GLOBE NEWSWIRE) -- Athersys today announced it was named for the second year in Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Athersys' revenues grew 217% during this period and ranked 351st i...
|
|
Athersys Reports Third Quarter 2012 Results
Nov 8, 2012
|
26.8 KB |
|
| |
CLEVELAND, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the third quarter ended September 30, 2012. Third quarter and recent highlights include:
Received net proceeds of approximately $21.1 million through the issuance of 22,772,300 shares of common stock (including the full e...
|
|
Athersys Announces Exercise of Overallotment Option
Nov 6, 2012
|
16.7 KB |
|
| |
CLEVELAND, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it received $2.8 million of net proceeds from the exercise, in full, of the underwriters' over-allotment option for 2,970,300 shares of its common stock. Taking this into account, Athersys sold a total of 22,772,300 shares of its common stock, representing...
|
|
Athersys Receives Cell Therapy Manufacturing Award
Nov 1, 2012
|
18.0 KB |
|
| |
CLEVELAND, Nov. 1, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced that its subsidiary, ReGenesys BVBA, recently received the BioProcess International Award for the "Technical Application of the Decade" in Manufacturing for its use of an automated bioreactor system for the production of MultiStem®, Athersys' proprietary, off-th...
|
|
Athersys to Host Third Quarter 2012 Financial Results Call
Oct 26, 2012
|
15.6 KB |
|
| |
CLEVELAND, Oct. 26, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced it will release its third quarter 2012 financial results at approximately 4:00 PM (Eastern Time) on Thursday, November 8, 2012, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen, Chairman and Chief ...
|
|
Athersys Prices Public Offering of Common Stock
Oct 26, 2012
|
15.4 KB |
|
| |
CLEVELAND, Oct. 26, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has priced its offering of common stock. The Company has agreed to sell 19,802,000 shares of common stock through an underwritten public offering at $1.01 per share, which was the closing price of its common stock on October 25, 2012. In connection wit...
|
|
|
= add release to Briefcase |
|
 |
|
May 22, 2013
9:58 AM ET
$1.85  0.01
Quotes delayed at least 20 minutes.
Information provided by eSignal.
|
|
 |
|
